Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

173054

registered interest
date	12/01/2015
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Military Aircraft
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Defence, if he will make it his policy to invest in the upgrade of the A400M aircraft for use in special operations; what lessons his Department learned from the time taken to upgrade the C130J aircraft for that role in terms of (a) foregone capability and (b) increased costs; what estimate he has made of the (i) ability of the A400M to withstand an attack in comparison with the C130J and (ii) comparative cost of keeping the C130J in service for this role and introducing an upgraded A400M; and if he will make a statement.
tabling member constituency	New Forest East
tabling member printed	Dr Julian Lewis
uin	220423
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>The A400M is planned to replace the C130J. The Department is currently considering upgrade requirements for the use of A400M across the span of operations. It is the policy of the Government not to comment on Special Forces matters.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 20/01/2015 16:24:31 answering member 1542 label Biography information for Philip Dunne
tabling member	54 label Biography information for Sir Julian Lewis

173200

registered interest
date	12/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much of the Cancer Drugs Fund was spent on pancreatic cancer drugs in each year since 2010.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	220490
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>NHS England has advised that there is currently one anti-cancer therapy available through the Cancer Drugs Fund that is used in pancreatic cancers. This is Abraxane (albumin bound paclitaxel).</p><p> </p><p> </p><p> </p><p>NHS England has estimated that, since Abraxane was added to the national Cancer Drugs Fund list in March 2014, the estimated spend in that financial year was approximately £13,000.</p><p> </p><p> </p><p> </p><p>Based on current application rates for this drug, NHS England estimates that approximately £4.09 million will be spent on this drug in 2014-15.</p><p> </p><p> </p><p> </p><p>Prior to April 2013, information on the indication for which a cancer drug was provided through the Fund was not collected.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/01/2015 13:35:17 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

172442

registered interest
date	07/01/2015
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Cats: Animal Welfare
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Environment, Food and Rural Affairs, if she will take steps to reduce the number of fatal shootings of cats; and if she will make a statement.
tabling member constituency	Derby North
tabling member printed	Chris Williamson
uin	219993
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>The Government considers that animal cruelty is abhorrent. In addition to strict firearms legislation governing the possession carrying and use of guns, it is already an offence to cause unnecessary suffering to an animal. All such incidents should be reported to the police who have the necessary powers to investigate.</p><p> </p> answering member constituency Camborne and Redruth answering member printed George Eustice question first answered 20/01/2015 15:01:15 answering member 3934 label Biography information for George Eustice
tabling member	3976 label Biography information for Chris Williamson

172302

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what consultation has taken place about the possibility of a reduction in funding for the national HIV prevention programme.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3885
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>We have no plans to reduce funding for the national HIV prevention programme for 2015-16.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3884 HL3886 question first answered 20/01/2015 11:57:59 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

172303

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the possible impact of a reduction in funding for the national HIV prevention programme from April 2015 on rates of HIV transmission in the United Kingdom.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3886
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>We have no plans to reduce funding for the national HIV prevention programme for 2015-16.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3884 HL3885 question first answered 20/01/2015 11:57:58 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

172304

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government why the National Institute for Health and Care Excellence guidance on the use of sofosbuvir in the treatment of hepatitis C has not been published nearly 11 months after it received its marketing authorisation.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3887
answer	answer is ministerial correction date of answer 19/01/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) was asked to develop technology appraisal guidance on the use of sofosbuvir within its marketing authorisation for the treatment of chronic hepatitis C in October 2013. Sofosbuvir received its marketing authorisation for this indication in January 2014.</p><p> </p><p> </p><p> </p><p>NICE published initial draft guidance in June 2014 which stated it was minded not to recommend use of sofosbuvir within its marketing authorisation and requested further information from the manufacturer. NICE published further draft guidance for consultation in August 2014, in which it recommended sofosbuvir for certain patients. Following consideration of the responses to this consultation on its draft recommendations, NICE requested further analyses from the company, which necessitated additional Committee discussion. NICE then carried out a further consultation in December on a proposal to extend the mandatory timescale for National Health Service commissioners to fund its recommendations on sofosbuvir. A similar consultation was also undertaken for simeprevir, another drug currently undergoing a NICE appraisal for chronic hepatitis C. A timeline of the process for the development of NICE’s guidance on sofosbuvir is published at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/indevelopment/gid-tag445" target="_blank">www.nice.org.uk/guidance/indevelopment/gid-tag445</a>.</p><p> </p><p> </p><p> </p><p>We have not made an assessment of the impact of this delay on patients with hepatitis C. Until NICE’s final guidance comes into effect, NHS England has in place an interim commissioning policy on sofosbuvir with ledipasvir and an interim policy for simeprevir which makes these treatments available to patients meeting specified clinical criteria during 2014-15. So far, this has made an additional £38 million available to cure patients at risk of liver failure. In addition, NHS England has made an assessment of need for patients with cirrhosis from April 2015 and will be finalising its plans shortly for this wider patient group.</p><p> </p><p> </p><p> </p><p>NICE’s consultation on extending the funding period closed in December and we understand that it expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, shortly. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3888 HL3889 question first answered 19/01/2015 12:14:44 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

172305

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the impact of the delay in the publication of the National Institute for Health and Care Excellence guidance on sofosbuvir on the health of patients with liver cirrhosis caused by hepatitis C.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3888
answer	answer is ministerial correction date of answer 19/01/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) was asked to develop technology appraisal guidance on the use of sofosbuvir within its marketing authorisation for the treatment of chronic hepatitis C in October 2013. Sofosbuvir received its marketing authorisation for this indication in January 2014.</p><p> </p><p> </p><p> </p><p>NICE published initial draft guidance in June 2014 which stated it was minded not to recommend use of sofosbuvir within its marketing authorisation and requested further information from the manufacturer. NICE published further draft guidance for consultation in August 2014, in which it recommended sofosbuvir for certain patients. Following consideration of the responses to this consultation on its draft recommendations, NICE requested further analyses from the company, which necessitated additional Committee discussion. NICE then carried out a further consultation in December on a proposal to extend the mandatory timescale for National Health Service commissioners to fund its recommendations on sofosbuvir. A similar consultation was also undertaken for simeprevir, another drug currently undergoing a NICE appraisal for chronic hepatitis C. A timeline of the process for the development of NICE’s guidance on sofosbuvir is published at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/indevelopment/gid-tag445" target="_blank">www.nice.org.uk/guidance/indevelopment/gid-tag445</a>.</p><p> </p><p> </p><p> </p><p>We have not made an assessment of the impact of this delay on patients with hepatitis C. Until NICE’s final guidance comes into effect, NHS England has in place an interim commissioning policy on sofosbuvir with ledipasvir and an interim policy for simeprevir which makes these treatments available to patients meeting specified clinical criteria during 2014-15. So far, this has made an additional £38 million available to cure patients at risk of liver failure. In addition, NHS England has made an assessment of need for patients with cirrhosis from April 2015 and will be finalising its plans shortly for this wider patient group.</p><p> </p><p> </p><p> </p><p>NICE’s consultation on extending the funding period closed in December and we understand that it expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, shortly. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3887 HL3889 question first answered 19/01/2015 12:14:44 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

172306

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of NHS England’s proposal to delay implementation of guidance on sofosbuvir for the treatment of hepatitis C.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3889
answer	answer is ministerial correction date of answer 19/01/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) was asked to develop technology appraisal guidance on the use of sofosbuvir within its marketing authorisation for the treatment of chronic hepatitis C in October 2013. Sofosbuvir received its marketing authorisation for this indication in January 2014.</p><p> </p><p> </p><p> </p><p>NICE published initial draft guidance in June 2014 which stated it was minded not to recommend use of sofosbuvir within its marketing authorisation and requested further information from the manufacturer. NICE published further draft guidance for consultation in August 2014, in which it recommended sofosbuvir for certain patients. Following consideration of the responses to this consultation on its draft recommendations, NICE requested further analyses from the company, which necessitated additional Committee discussion. NICE then carried out a further consultation in December on a proposal to extend the mandatory timescale for National Health Service commissioners to fund its recommendations on sofosbuvir. A similar consultation was also undertaken for simeprevir, another drug currently undergoing a NICE appraisal for chronic hepatitis C. A timeline of the process for the development of NICE’s guidance on sofosbuvir is published at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/indevelopment/gid-tag445" target="_blank">www.nice.org.uk/guidance/indevelopment/gid-tag445</a>.</p><p> </p><p> </p><p> </p><p>We have not made an assessment of the impact of this delay on patients with hepatitis C. Until NICE’s final guidance comes into effect, NHS England has in place an interim commissioning policy on sofosbuvir with ledipasvir and an interim policy for simeprevir which makes these treatments available to patients meeting specified clinical criteria during 2014-15. So far, this has made an additional £38 million available to cure patients at risk of liver failure. In addition, NHS England has made an assessment of need for patients with cirrhosis from April 2015 and will be finalising its plans shortly for this wider patient group.</p><p> </p><p> </p><p> </p><p>NICE’s consultation on extending the funding period closed in December and we understand that it expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, shortly. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3887 HL3888 question first answered 19/01/2015 12:14:44 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

172307

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the answer by Earl Howe on 16 December 2014 (HL Deb, cols 101–2), whether they sought the endorsement of (1) the British Medical Association, (2) the General Medical Council, and (3) any of the Royal Medical Colleges, for their Guidance in Relation to the Requirements of the Abortion Act 1967; and if so, what were the respective responses.
tabling member printed	Lord Alton of Liverpool
uin	HL3890
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>The Department developed the guidance in conjunction with a number of professional organisations and bodies; these included the British Medical Association, the General Medical Council, Nursing and Midwifery Council and the Royal College of Obstetricians and Gynaecologists. The guidance was published solely by the Department.</p><p> </p> answering member printed Earl Howe question first answered 20/01/2015 14:15:56 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

172308

registered interest
date	06/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government further to the answer by Earl Howe on 16 December 2014 (HL Deb, cols 101–2), what status the Guidance in Relation to the Requirements of the Abortion Act 1967 has, and whether abortion providers are legally required to comply with it.
tabling member printed	Lord Alton of Liverpool
uin	HL3891
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>When exercising power under section 1(3) of the Abortion Act 1967 to approve a place for the termination of pregnancy, the Secretary of State will only consider a provider if they undertake to comply with the Required Standard Operating Procedures which in turn require compliance with the Department’s guidance.</p><p> </p> answering member printed Earl Howe question first answered 20/01/2015 11:57:19 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool